Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 288

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Fabarius, Alice, Leitner, Armin, Hochhaus, Andreas, Müller, Martin C., Hanfstein, Benjamin, Haferlach, Claudia, Göhring, Gudrun, Schlegelberger, Brigitte, Jotterand, Martine, Reiter, Andreas, Jung-Munkwitz, Susanne, Proetel, Ulrike, Schwaab, Juliana, Hofmann, Wolf-Karsten, Schubert, Jörg, Einsele, Hermann, Ho, Anthony D., Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Spiekermann, Karsten, Baerlocher, Gabriela M., Lauseker, Michael, Pfirrmann, Markus, Hasford, Joerg, Saussele, Susanne, Hehlmann, Rüdiger, for the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group·2011·Blood

Abstract

The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on time to complete cytogenetic (CCR) and major molecular remission (MMR) and progression-free (PFS) and overall survival (OS) was analyzed using data from 1151 Philadelphia chromosome–positive (Ph+) CML patients randomized to the German CML Study IV. At diagnosis, 1003 of 1151 patients (87%) had standard t(9;22)(q34;q11) only, 69 patients (6.0%) had variant t(v;22), and 79 (6.9%) additional cytogenetic aberrations (ACAs). Of these, 38 patients (3.3%) lacked the Y chromosome (−Y) and 41 patients (3.6%) had ACAs except −Y; 16 of these (1.4%) were major route (second Philadelphia [Ph] chromosome, trisomy 8, isochromosome 17q, or trisomy 19) and 25 minor route (all other) ACAs. After a median observation time of 5.3 years for patients with t(9;22), t(v;22), −Y, minor- and major-route ACAs, the 5-year PFS was 90%, 81%, 88%, 96%, and 50%, and the 5-year OS was 92%, 87%, 91%, 96%, and 53%, respectively. In patients with major-route ACAs, the times to CCR and MMR were longer and PFS and OS were shorter (P < .001) than in patients with standard t(9;22). We conclude that major-route ACAs at diagnosis are associated with a negative impact on survival and signify progression to the accelerated phase and blast crisis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-08-373902

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 288

Metadata

Authors
Fabarius, A., Leitner, A., Hochhaus, A., Müller, M. C., Hanfstein, B., Haferlach, C., Göhring, G., Schlegelberger, B., Jotterand, M., Reiter, A., Jung-Munkwitz, S., Proetel, U., Schwaab, J., Hofmann, W.-K., Schubert, J., Einsele, H., Ho, A. D., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Baerlocher, G. M., Lauseker, M., Pfirrmann, M., Hasford, J., Saussele, S., Hehlmann, R., & for the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group
Venue
Blood
Published
2011-12-22
Volume
118
Issue
26
Pages
6760-6768
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2033661259
Cited by
288
References
40
FWCI
12.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. https://app.cochat.ai/papers/10.1182/blood-2011-08-373902
The paper
Fabarius, A., Leitner, A., Hochhaus, A., Müller, M. C., Hanfstein, B., Haferlach, C., Göhring, G., Schlegelberger, B., Jotterand, M., Reiter, A., Jung-Munkwitz, S., Proetel, U., Schwaab, J., Hofmann, W.-K., Schubert, J., Einsele, H., Ho, A. D., Falge, C., Kanz, L., . . . for the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group. (2011). Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. https://doi.org/10.1182/blood-2011-08-373902

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.